The Europe Infectious Diseases Diagnostics Market Size is anticipated to grow at a 7.34% CAGR from 2021 to 2026. The European market was estimated to be valued at USD 4.70 billion in 2021 and is relied upon to achieve USD 6.70 billion by 2026.
Europe held the second-largest share of the global IDD market in 2020. This region is projected to witness a single-digit growth rate during the forecast period due to the growing adoption of premium diagnostic techniques, which is expected to accelerate the IDD market growth in the European region. The European infectious diseases diagnostics market is further driven by the factors such as increasing healthcare costs, rising healthcare expenditure, growing acceptance of premium diagnostic methods, rising demand for novel diagnostic tests to control infectious diseases, investments from both government and private organizations for the R&D.
The high price of the disease diagnostic test kits is the prime factor restraining the market growth. The scarcity of reimbursement for a few infectious diseases is also impeding the market. Moreover, the unaffordable efficient diagnostic tools are likely to obstruct the market. Some of the medical tests have witnessed a 40% decline in reimbursements for the last 40 years.
This research report on the European Infectious Diseases Diagnostics Market has been segmented and sub-segmented into the following categories:
By Product:
By Application:
By Technology:
By End User:
By Country:
The European region is expected to account for the second-largest share in the global infectious diseases diagnostics market during the forecast period. Among various countries of Europe, the German infectious disease diagnostics market is expected to lead from 2021 to 2026 due to the assumption of high-end IDD with the help of molecular technologies that help the region grow further.
The UK infectious disease diagnostics market is expected to witness rapid growth during the forecast period due to the technological advancements in diagnostic instruments. The government’s proposals to improve suitable healthcare infrastructure in existing economies boost the growth of the disease diagnostics market during the forecast timeline. Moreover, the rising assumption of technologically advanced visual diagnostic instruments in healthcare organizations and increasing approval and acceptance of developed molecular techniques bolster the market growth.
KEY MARKET PLAYERS:
A few of the notable companies operating in the European infectious disease diagnostics market profiled in this report are Abbott Laboratories, bioMérieux SA, Hologic, Inc., Danaher Corporation, Becton, Dickinson and Company, Cepheid, Inc., Thermo Fisher Scientific Inc., Roche Diagnostics, Alere Inc., DiaSorin S.p.A., Quidel Corporation, and Bio-Rad Laboratories, Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Instruments & Analyzers
5.1.3 Consumables
5.1.3.1 Assays and Reagents
5.1.4 Services & Softwares
5.1.5 Y-o-Y Growth Analysis, By Product
5.1.6 Market Attractiveness Analysis, By Product
5.1.7 Market Share Analysis, By Product
5.2 Technique
5.2.1 Introduction
5.2.2 Traditional Diagnostic Techniques
5.2.2.1 Immunodiagnostics
5.2.2.2 Microscopy
5.2.2.3 Biochemical Characterization
5.2.3 Molecular Diagnostics
5.2.3.1 PCR
5.2.3.2 INAAT
5.2.3.2 Hybridization
5.2.3.3 DNA Sequencing & NGS
5.2.3.4 Microarray
5.2.3.5 Others
5.2.4 Y-o-Y Growth Analysis, By Technique
5.2.5 Market Attractiveness Analysis, By Technique
5.2.6 Market Share Analysis, By Technique
5.3 Application
5.3.1 Introduction
5.3.2 Hepatitis B
5.3.3 Hepatitis C
5.3.4 Human Immunodeficiency Virus (HIV)
5.3.5 Tuberculosis (TB)
5.3.6 Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG)
5.3.7 Human papillomavirus (HPV)
5.3.8 Methicillin-resistant Staphylococcus aureus (MRSA)
5.3.9 Others
5.3.10 Y-o-Y Growth Analysis, By Application
5.3.11 Market Attractiveness Analysis, By Application
5.3.12 Market Share Analysis, By Application
5.4 End User
5.4.1 Introduction
5.4.2 Hospitals Laboratories
5.4.3 Physician office Labs
5.4.4 Academics
5.4.5 Others
5.4.6 Y-o-Y Growth Analysis, By End User
5.4.7 Market Attractiveness Analysis, By End User
5.4.8 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Technique
6.1.3.4 By Application
6.1.3.5 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Technique
6.1.4.4 By Application
6.1.4.5 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Technique
6.1.5.4 By Application
6.1.5.5 By End User
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Abbott Laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 bioMérieux SA &
Related Reports
